My watch list
my.bionity.com  
Login  

CureVac and Arcturus Therapeutics announce broad strategic collaboration

Develop next generation of lipid-mediated mRNA therapeutics

08-Jan-2018

CureVac AG and Arcturus Therapeutics Ltd. announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

Under the agreement, the companies will collaborate to develop up to four molecular therapy products for rare diseases using Curevac’s optimized natural mRNA sequence (RNAoptimizer®) and Arcturus’s lipid-mediated nucleic acid delivery system (LUNAR™). The agreement focuses on developing mRNA therapeutics for enzyme replacement and antibody generation. Development costs will be shared between the companies, with plans to co-commercialize products in the future under a profit sharing arrangement. The first mRNA therapy to be jointly developed and potentially commercialized by the companies will target ornithine transcarbamylase (OTC) deficiency, a genetic disease characterized by the accumulation of ammonia in the blood. The collaboration also grants CureVac access to the full suite of Arcturus’s lipid-mediated delivery intellectual property to enable the development of additional mRNA product candidates.

“This collaboration for up to four products establishes a sound relationship with Arcturus, which we believe is one of the leaders in developing lipid-mediated delivery systems for mRNA molecules,” said Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac. “Just as important, we are excited to have secured access to Arcturus’s leading intellectual property rights for future product development in molecular therapies. This partnership combines both companies’ technology platforms with the expertise necessary to develop the next generation of therapeutics based on the considerable potential of mRNA.”

“We are thrilled to combine Arcturus’s platform technologies and expertise with CureVac’s recognized capabilities in mRNA construct optimization and GMP manufacturing to co-develop messenger RNA medicines for patients in need,” said Joseph Payne, President and CEO of Arcturus. “We believe our collaboration with CureVac has the potential to help reduce costs, mitigate manufacturing risks, and accelerate our timelines for ushering quality mRNA medicines into the clinic.”

Facts, background information, dossiers
  • messenger RNA
More about CureVac
  • News

    CureVac to Pursue mRNA Vaccines Against Flu and Malaria

    CureVac AG announced the awarding of two new grants from the Bill & Melinda Gates Foundation. The programs will leverage CureVac’s RNActive® prophylactic vaccine technology to develop mRNA-based vaccines designed to prevent influenza and malaria infection. These vaccines, which are flexible ... more

    CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

    CureVac AG announced the groundbreaking of its industrial-scale, GMP-compliant production facility at its headquarters in Tübingen, Germany. The novel production facility – called GMP IV – will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expe ... more

    Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) techno ... more

  • Job Offers

    Scientist (f/m) Immunology and Infectious Diseases

    CureVac AG is a biopharmaceutical company researching, developing and producing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on innovative cancer immunotherapies and prophylactic vaccines. Currently, about 340 RNA people are striving to achieve our main goal: ... more

    Project Manager (f/m) – Prophylactic Vaccines

    CureVac AG is a biopharmaceutical company researching, developing and producing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on innovative cancer immunotherapies and prophylactic vaccines. Currently, about 340 RNA people are striving to achieve our main goal: ... more

    Senior Project Manager (f/m) - Oncology

    CureVac AG is a biopharmaceutical company researching, developing and producing novel drugs based on the natural molecule Messenger RNA (mRNA). Our focus is on innovative cancer immunotherapies and prophylactic vaccines. Currently, about 340 RNA people are striving to achieve our main goal: ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE